Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Pharma
AZ leans on cancer, rare disease muscle in solid Q2
In 2026’s second quarter, AstraZeneca generated revenue of nearly $15.4 million, growing 5% over the same period in 2025 at constant currencies.
Fraiser Kansteiner
Jul 27, 2026 10:21am
GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia
Jul 17, 2026 9:38am
AstraZeneca buys lung cancer drug Zegfrovy from Dizal for $1.5B
Jul 14, 2026 9:57am
FDA expands Padcev-Keytruda combo to more MIBC patients
Jul 10, 2026 1:10pm
AZ's China deals, Kailera-Hengrui—Fierce Pharma Asia
Jul 10, 2026 8:51am
AstraZeneca, Ionis shares slide with ATTR-CM trial failure
Jul 9, 2026 11:36am
